UBL7: A Protein Targeted for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

Target Name: UBL7-DT

NCBI ID: G440288

Other Name(s): UBL7 divergent transcript | UBL7-DT variant 1 | UBL7 divergent transcript, transcript variant 1 | UBL7-AS1

UBL7: A Protein Targeted for Cancer, Neurodegenerative Diseases and Autoimmune Disorders

UBL7-DT, or UBL7 divergent transcript, is a protein that has been identified as a potential drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. UBL7 is a transmembrane protein that is expressed in many different tissues and cells in the body. It is characterized by a long extracellular domain that is involved in several different interactions with other proteins, including interaction with the transcription factor NF-kappa-B.

One of the unique features of UBL7 is its ability to induce a response in cell culture models of cancer. In fact, studies have shown that UBL7 can induce cell proliferation, migration, and invasion in a variety of cancer cell lines, including breast, ovarian, and colorectal cancer cells. This suggests that UBL7 may be a useful drug target or biomarker for cancer treatment.

In addition to its potential as a cancer drug, UBL7 has also been identified as a potential biomarker for neurodegenerative diseases. Studies have shown that UBL7 is expressed in the brains of individuals with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, UBL7 has been shown to be involved in the development and progression of neurodegenerative diseases, which suggests that it may be a useful biomarker for these conditions.

Another potential application of UBL7 is as a target for the treatment of autoimmune disorders. Studies have shown that UBL7 is expressed in the tissues of individuals with a variety of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Additionally, UBL7 has been shown to play a role in the development and regulation of autoimmune diseases, which suggests that it may be a useful drug target or biomarker for the treatment of these conditions.

Overall, UBL7 is a protein that has been identified as a potential drug target or biomarker for a variety of conditions, including cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to fully understand the role of UBL7 in these conditions and to develop effective treatments.

Protein Name: UBL7 Divergent Transcript

More Common Targets